Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Camilla Levister on the Benefits of Artificial Pancreas Systems for Type 1 Diabetes
February 12th 2024Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, discusses how closed-loop systems benefit patients managing type 1 diabetes.
Read More
Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma
February 11th 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
Read More
15-Year Analysis Shows Decrease in Ovarian Cancer Incidence, Incidence-Based Mortality
February 9th 2024The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with epithelial cancer, especially in advanced stages.
Read More
Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain
February 8th 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.
Read More
Dr Mark Socinski on the Need for Lung Cancer Screening in Eligible Patients
February 7th 2024Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.
Read More
Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape
February 2nd 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.
Read More
CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds
February 2nd 2024In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.
Read More
Older Adults in Traditional Medicare Spend Weeks Per Year on Health Care Contact Days
February 1st 2024Days spent obtaining health care outside the home may show access to needed care, but also add up to substantial time, effort, and cost burdens to patients and those who care for them, according to the study authors.
Read More
Low Muscle Mass, Hypoalbuminemia Increase Mortality Risk in ADHF
January 28th 2024Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.
Read More
Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS
January 27th 2024The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.
Read More
Dr Melinda Aldrich on Disparities and the Importance of Screening in Lung Cancer
January 25th 2024Melinda Aldrich, PhD, MHE, associate professor in the Vanderbilt University School of Medicine in the division of genetic medicine, discussed her ongoing research aiming to identify the drivers of disparities in lung cancer outcomes in the US.
Read More
Female Patients Less Likely to Receive Guideline-Directed HFrEF Therapies vs Males
January 25th 2024A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients compared with male patients.
Read More
Bolus Insulin Injection Frequency, Smart Pen Engagement Linked With Glycemic Control in T1D
January 22nd 2024A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among young adult patients with type 1 diabetes (T1D).
Read More
Molly Mendenhall on Standardizing Comprehensive Biomarker Testing in NSCLC
January 18th 2024Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).
Read More
Real-Time CGM Shows Benefits Over Intermittently Scanned CGM in T1D
January 16th 2024In a systematic review and meta-analysis, real-time continuous glucose monitoring (CGM) demonstrated benefits in terms of time in range, hypoglycemia, and hyperglycemia among patients with type 1 diabetes (T1D).
Read More
Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL
January 12th 2024A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Read More
Dr Michael Gieske on Successes and Challenges in Increasing Lung Cancer Screening in Rural Regions
January 12th 2024Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, speaks to the success of the Rural Appalachian Lung Cancer Screening Initiative, along with challenges to implementing increased lung cancer screening.
Read More
Hypofractionated Chemoradiation Regimen With an Adaptive SABR Boost Shows Promise in NSCLC
January 12th 2024An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC).
Read More
Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups
January 10th 2024Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Read More
Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer
January 6th 2024Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.
Read More